Entrada Therapeutics (TRDA) Net Income towards Common Stockholders (2020 - 2026)

Entrada Therapeutics' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$39.7 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 128.93% year-over-year to -$39.7 million; the TTM figure through Mar 2026 stood at -$166.1 million (down 771.6% YoY), while the FY2025 annual figure was -$143.7 million, down 319.01% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$39.7 million, down from -$39.2 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $55.0 million in Q2 2024, with the low at -$44.1 million in Q3 2025.
• The 5-year median for Net Income towards Common Stockholders is -$21.7 million (2022), against an average of -$12.9 million.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders soared 452.05% in 2024, then plunged 3563.48% in 2025.
• Entrada Therapeutics' Net Income towards Common Stockholders stood at -$24.6 million in 2022, then surged by 61.42% to -$9.5 million in 2023, then surged by 111.9% to $1.1 million in 2024, then slumped by 3563.48% to -$39.2 million in 2025, then declined by 1.39% to -$39.7 million in 2026.
• Business Quant data shows TRDA's Net Income towards Common Stockholders at -$39.7 million in Q1 2026, -$39.2 million in Q4 2025, and -$44.1 million in Q3 2025.